Form 4: Charles River Laboratories Director Acquires Shares and Stock Options

Robert J. Bertolini, a director at Charles River Laboratories, recently acquired common stock and stock options in the company.

Summary

• On May 13, 2024, Robert J. Bertolini, a director of Charles River Laboratories International, Inc., acquired 559 shares of common stock at a price of $228.41 per share.
• Bertolini also acquired 394 shares of common stock in lieu of director service fees for the term commencing May 8, 2024, at the same price of $228.41 per share.
• Additionally, Bertolini acquired 1,311 stock options with an exercise price of $228.41, exercisable starting May 13, 2025, or the business day prior to the company's next annual meeting of shareholders, and expiring on May 13, 2034.
• Following these transactions, Bertolini directly owns 32,802 shares of common stock and 1,311 stock options.
• The restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director is increasing their stake in the company, suggesting confidence. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• A director's acquisition of company stock and options can be seen as a positive signal, indicating confidence in the company's future performance.
• The grant of stock in lieu of director fees aligns the director's interests with those of the shareholders.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. Director Bertolini's acquisition of shares and options suggests a positive outlook from within the company.

Comparison to Industry Standards

• Comparing Bertolini's transactions to those of directors at similar companies like Laboratory Corporation of America Holdings (LH) or Quest Diagnostics (DGX) could provide context on the scale and frequency of insider activity.
• Analyzing the vesting schedules and exercise prices of stock options against industry norms can reveal whether Charles River Laboratories' compensation practices are competitive.

Stakeholder Impact

• Shareholders may view the director's stock acquisition as a positive signal.
• Employees may see this as a sign of stability and confidence in the company's leadership.

Key Dates